Hiring in a biotech is unlike hiring in most other organisations. When your runway is measured in months and your pipeline depends on a small number of critical people, every appointment carries disproportionate weight. A wrong hire in a leadership role doesn't just create a performance problem. It can set back a clinical programme, damage investor confidence, or trigger a wider talent departure at a moment when the business can least afford it.
At the same time, the talent pool for many biotech functions is genuinely constrained. The number of people who combine deep scientific expertise in a specific modality with the operational experience and biotech-scale mindset these roles require is small. Finding them requires active sourcing and established networks. You can't post a job and wait.
One of the things that makes biotech talent strategy genuinely complex is that the skills you need change as the company develops. Early-stage discovery hiring looks completely different from late-stage clinical development or pre-launch commercial buildout. The person who's right for a lean, pre-IND environment often isn't the person who can manage a global Phase III programme, and vice versa.
This creates two recurring problems. The first is hiring too early for the current stage, bringing in a heavyweight who either gets frustrated by the constraints of an early-stage environment or reshapes the organisation around their preferences before the company is ready. The second is hiring too late for the next stage, not starting the search until you need someone in the role, then discovering that the lead time for senior and specialist hires is longer than your timeline allows.
Getting that timing right requires someone who understands where the company is and where it's headed, and can translate that into a realistic talent strategy.
Biotech recruitment isn't a monolith. The talent landscape for a company developing small molecule drugs looks completely different from one working in cell and gene therapy, RNA therapeutics, or biologics. The relevant networks, the candidate profiles, the competitive dynamics, and the employer proposition that will resonate with strong candidates all differ by modality.
A recruiter who covers pharma services broadly may know the general landscape but will often struggle to identify the genuinely strong candidates in a specific modality. They don't have the relationships, the technical vocabulary, or the market intelligence to distinguish between candidates who are right for the role and those who look right on paper.
For roles in cell and gene therapy manufacturing, RNA platform science, or first-in-class regulatory strategy, modality-specific knowledge isn't a nice-to-have. It's the difference between a shortlist that contains real options and one that wastes everyone's time.
The biotechs that build strong teams tend to be honest about what they can offer candidates. Not just the science and the mission, but the reality of what working there looks like at this stage of development. Strong candidates have choices. They're doing their diligence on your organisation with the same rigour you're applying to them. Overpromising on structure, resource, or trajectory will surface quickly, and it damages your reputation with the people you most need to attract.
They also tend to start searches earlier than feels necessary. For senior and specialist roles in biotech, particularly in areas like CMC leadership, clinical development, and regulatory strategy, six months isn't an unusual lead time. The candidate you want is probably employed, not actively looking, and will need time to consider a move carefully. That's a process you can only run if you haven't left it until the role is critical.
Working with recruiters who've built genuine networks in your specific modality, and who understand the particular demands of each growth stage, gives you access to candidates you wouldn't find any other way, and a more realistic view of what the market will support.